更新于：2024-09-26
Aminopterin
氨基蝶呤
更新于：2024-09-26
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
结构
分子式C19H20N8O5 |
InChIKeyTVZGACDUOSZQKY-LBPRGKRZSA-N |
CAS号54-62-6 |
关联
6
项与 氨基蝶呤 相关的临床试验A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
A Phase 2 Double-Blind, Placebo-Controlled, Randomized Dose Finding Study For The Efficacy And Safety Of Aminopterin In Methotrexate-Naive Rheumatoid Arthritis
A Randomized Phase 1 Study Comparing The Safety and Oral Pharmacokinetics Of 0.25 mg and 1.0 mg Aminopterin Tablets In Human Subjects With Psoriasis
100 项与 氨基蝶呤 相关的临床结果
登录后查看更多信息
100 项与 氨基蝶呤 相关的转化医学
登录后查看更多信息
100 项与 氨基蝶呤 相关的专利（医药）
登录后查看更多信息
1,051
项与 氨基蝶呤 相关的文献（医药）2024-10-12Journal of biomolecular structure & dynamics
Shedding light into the biological activity of aminopterin,
via
molecular structural, docking, and molecular dynamics analyses
Article
作者: Ozel, Aysen E. ; Celik, Sefa ; Akyuz, Sevim ; Yilmaz, Gozde
In this study, the structural and anticancer properties of aminopterin, as well as its antiviral characteristics, were elucidated. The preferred conformations of the title molecule were investigated with semiempirical AM1 method, and the obtained the lowest energy conformer was then optimized by using density functional (DFT/B3LYP) method with 6-311++G(d,p) as basis set. The vibrational frequencies of the optimized structure were calculated by the same level of theory and were compared with the experimental values. The vibrational assignments were performed based on the computed potential energy distribution (PED) of the vibrational modes. The molecular electrostatic potential (MEP) and frontier molecular orbitals (HOMO, LUMO) analyses were carried out for the optimized structure and the chemical reactivity has been scrutinized. To enlighten the biological activity of aminopterin as anticancer and anti-COVID-19 agents, aminopterin was docked into DNA, αIIBβ3 and α5β1integrins, human dihydrofolate reductase, main protease (Mpro) of SARS-CoV-2 and SARS-CoV-2/ACE2 complex receptor. The binding mechanisms of aminopterin with the receptors were clarified. The molecular docking results revealed the strong interaction of the aminopterin with DNA (-8.2 kcal/mol), αIIBβ3 and α5β1 integrins (-9.0 and -10.8 kcal/mol, respectively), human dihydrofolate reductase (-9.7 kcal/mol), Mpro of SARS-CoV-2 (-6.7 kcal/mol), and SARS-CoV-2/ACE2 complex receptor (-8.1 kcal/mol). Moreover, after molecular docking calculations, top-scoring ligand-receptor complexes of the aminopterin with SARS-CoV-2 enzymes (6M03 and 6M0J) were subjected to 50 ns all-atom MD simulations to investigate the ligand-receptor interactions in more detail, and to determine the binding free energies accurately. The predicted results indicate that the aminopterin may significantly inhibit SARS-CoV-2 infection. Thus, in this study, as both anticancer and anti-COVID-19 agents, the versatility of the biological activity of aminopterin was shown.Communicated by Ramaswamy H. Sarma.
2024-02-06ACS omega
Biocompatible, Injectable, and Self-Healing Poly(N-vinylpyrrolidone)/Carboxymethyl Cellulose Hydrogel for Drug Release
Article
作者: Yu, Meiqiong ; Yang, Yuqing ; Pan, Yuwei ; Mondal, Ajoy Kanti ; Tang, Zuwu ; Lin, Xinxing
Hydrogels have drawn intensive attention as fascinating materials for biomedicine. However, fabricating hydrogels with injectable and self-healing properties remains a challenge. Herein, we reported a biocompatible poly(N-vinylpyrrolidone)/carboxymethyl cellulose (PVP/CMC) hydrogel with excellent injectable and self-healing properties. The PVP/CMC hydrogel exhibits good biocompatible, injectable, and self-healing properties. The sol-gel transition of PVP/CMC hydrogels demonstrates an outstanding self-healing behavior, and the bisected hydrogels can self-heal within 30 s. The hydrogels have a good swelling ratio, and the swelling ratio increases with increasing amount of CMC in PVP and reaches a maximum of 2850% at a 1.0:1.5 PVP and CMC ratio. In addition, the hydrogel possesses excellent drug release capacity, and its drug release rate reaches 70%. Moreover, the release of 4-aminosalicylic acid (4-ASA) in the hydrogel can be controlled by adjusting the proportion of the hydrogel. The PVP/CMC hydrogel with excellent biocompatible, injectable, and self-healing properties has great potential for applications in drug release.
2023-11-01Legal medicine (Tokyo, Japan)
Simple quantification of propofol and its metabolites in blood and urine using gas chromatography–tandem mass spectrometry (GC–MS/MS)
Article
作者: Bai, Huiru ; Gu, Jie ; Wurita, Amin ; Hasegawa, Koutaro ; Wang, Yue ; Dai, Yinyin ; Zhao, Kundi ; Li, Yaqing
An analytical method which was used for the simultaneous detection and quantification of propofol and its metabolites in human blood and urine by gas chromatography-tandem mass spectrometry (GC-MS/MS) was newly established and applied to authentic human samples obtained from the deceased. The QuEChERS method was employed, and then analyzed by GC-MS/MS. We separately used sulfatase and β-glucuronidase to hydrolyze the urine sample and calculated the increase of propofol and 4-hydroxypropofol before and after the hydrolysis. The results of urinary concentrations in urine from the subject were: 4.88 μg/mL for propofol, 0.53 μg/mL for 4-hydroxypropofol, 3.35 μg/mL for propofol-glucuronide, 0.31 μg/mL for the total concentration of 1-(2,6-diisopropyl-1,4-quinol)-glucuronide plus 4-(2,6-diisopropyl-1,4-quinol)-glucuronide, and 0.39 μg/mL for 4-(2,6- diisopropyl-1,4-quinol)-sulfate. The lower limit of quantification was 10 ng/mL for all determined compounds; the extraction recoveries were not less than 57.2 %. Intraday and interday precisions and accuracies were all less than 10 %. The calibration curves for propofol and 4-hydroxypropofol in human urine showed the correlation values of not less than 0.999; propofol and 4-hydroxypropofol in blood also presented good linearities in the concentration ranges of 0.1-10 μg/mL. The two compounds had good stability within 7 days at 25, 4, and -20 ℃. To our knowledge, this is the first trial to establish a simple and reliable method to simultaneously detect and quantify of propofol and its phase I and II metabolites in human blood and urine samples by GC-MS/MS.
2
项与 氨基蝶呤 相关的新闻（医药）2023-12-15
·药融圈
疫苗细胞疗法核酸药物寡核苷酸
100 项与 氨基蝶呤 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 银屑病 | 临床2期 | 美国 | 2018-11-01 | |
| 类风湿关节炎 | 临床2期 | 乌克兰 | 2013-02-01 | |
| 复发性子宫内膜癌 | 临床2期 | 美国 | 1998-01-01 | |
| 难治性急性白血病 | 临床2期 | 美国 | 1997-07-01 | |
| 难治性白血病 | 临床2期 | 美国 | 1997-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 19 | (LD-Aminopterin Oral Capsule) | 選衊廠壓鏇艱構壓鬱繭(壓願遞蓋鹽觸蓋壓願觸) = 糧膚憲獵衊蓋簾糧網衊 鑰糧壓願艱膚淵齋夢衊 (鏇鏇鑰觸繭衊鑰鏇鏇網, 鹽顧遞淵艱選鏇範壓齋 ~ 選憲夢願構築顧構選鏇) 更多 | - | 2023-04-14 | ||
Placebo oral capsule (Placebo Oral Capsule) | 選衊廠壓鏇艱構壓鬱繭(壓願遞蓋鹽觸蓋壓願觸) = 壓遞廠蓋網鬱艱積製淵 鑰糧壓願艱膚淵齋夢衊 (鏇鏇鑰觸繭衊鑰鏇鏇網, 廠淵願膚獵鬱鬱蓋壓憲 ~ 齋艱鏇膚鬱觸構糧窪網) 更多 | ||||||
临床2期 | 60 | Daunomycin+Cyclophosphamide+leucovorin+Hydrocortisone+6-thioguanine+aminopterin+6-mercaptopurine+dexamethasone+Vincristine+Methotrexate+Cytarabine+L-Asparaginase (Arm 2 High Risk) | 衊網糧積襯艱範餘網膚(簾鏇齋齋鏇衊糧鑰積壓) = 範繭鹽鏇願衊繭衊壓構 襯觸艱鹹醖衊窪網壓膚 (鹹遞襯製窪齋淵獵鬱窪, 壓膚襯鹽餘餘網蓋構憲 ~ 廠製糧膚鏇憲鏇憲製窪) 更多 | - | 2014-06-09 | ||
Daunomycin+leucovorin+Hydrocortisone+6-mercaptopurine+dexamethasone+Methotrexate+Vincristine+Cytarabine+L-Asparaginase (Arm 1 Standard Risk) | 膚蓋鹹廠鬱鑰製淵鑰夢(夢構蓋蓋廠醖鏇鹹獵襯) = 鏇鹽廠衊淵網夢鑰膚鏇 壓鑰醖選夢餘簾鹹廠簾 (壓鬱齋鹹膚襯壓艱衊淵, 艱膚夢構蓋觸簾鬱窪蓋 ~ 鬱遞製築齋積醖艱膚餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用